MX2021005949A - Vacuna estable contra clostridium difficile. - Google Patents

Vacuna estable contra clostridium difficile.

Info

Publication number
MX2021005949A
MX2021005949A MX2021005949A MX2021005949A MX2021005949A MX 2021005949 A MX2021005949 A MX 2021005949A MX 2021005949 A MX2021005949 A MX 2021005949A MX 2021005949 A MX2021005949 A MX 2021005949A MX 2021005949 A MX2021005949 A MX 2021005949A
Authority
MX
Mexico
Prior art keywords
clostridium difficile
conjugate
vaccine against
synthetic saccharide
stable vaccine
Prior art date
Application number
MX2021005949A
Other languages
English (en)
Inventor
Claney Lebev Pereira
Madhu Emmadi
Marilda P Lisboa
Daniel Knopp
Bopanna Monnanda
Bonin Arne Von
Original Assignee
Idorsia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idorsia Pharmaceuticals Ltd filed Critical Idorsia Pharmaceuticals Ltd
Publication of MX2021005949A publication Critical patent/MX2021005949A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Pathology (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)

Abstract

La presente invención se refiere a un sacárido sintético de fórmula general (I) que está relacionado con el polisacárido PS-II de la superficie celular de Clostridium difficile y el conjugado del mismo. Dicho sacárido sintético, dicho conjugado y composición farmacéutica que contiene dicho sacárido sintético o dicho conjugado son útiles para la prevención y/o el tratamiento de enfermedades asociadas con Clostridium difficile. Además, el sacárido sintético de fórmula general (I) es útil como marcador en ensayos inmunológicos para la detección de anticuerpos contra la bacteria Clostridium difficile.
MX2021005949A 2018-11-22 2019-11-22 Vacuna estable contra clostridium difficile. MX2021005949A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18207920 2018-11-22
PCT/EP2019/082331 WO2020104697A1 (en) 2018-11-22 2019-11-22 Stable vaccine against clostridium difficile

Publications (1)

Publication Number Publication Date
MX2021005949A true MX2021005949A (es) 2021-07-06

Family

ID=64650105

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021005949A MX2021005949A (es) 2018-11-22 2019-11-22 Vacuna estable contra clostridium difficile.

Country Status (11)

Country Link
US (1) US20230045939A1 (es)
EP (1) EP3883944A1 (es)
JP (1) JP7296459B2 (es)
KR (1) KR20210094573A (es)
CN (1) CN113166186A (es)
AU (1) AU2019383549A1 (es)
BR (1) BR112021008279A2 (es)
CA (1) CA3120451A1 (es)
EA (1) EA202191393A1 (es)
MX (1) MX2021005949A (es)
WO (1) WO2020104697A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024514531A (ja) * 2021-04-02 2024-04-02 マトリバックス，インコーポレーテッド クロストリディオイデス・デフィシル（ｃｌｏｓｔｒｉｄｉｏｄｅｓ ｄｉｆｆｉｃｉｌｅ）感染を処置する方法および組成物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996027379A1 (en) * 1995-03-08 1996-09-12 The Scripps Research Institute Carbopeptoids and carbonucleotoids
DE19648681A1 (de) 1996-11-25 1998-05-28 Hoechst Ag Antiadhäsive Benzoesäure-Derivate
ES2534671T3 (es) 2007-09-11 2015-04-27 University Of Guelph Inmunógenos polisacáridos de la Clostridium difficile
US20130315959A1 (en) 2010-12-24 2013-11-28 Novartis Ag Compounds
EP2683401A1 (en) 2011-03-08 2014-01-15 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Oligosaccharides and oligosaccharide-protein conjugates derived from clostridium difficile polysaccharide ps-ii, methods of synthesis and uses thereof, in particular as a vaccine
US9815889B2 (en) * 2011-08-02 2017-11-14 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. Antibodies for prevention and treatment of diseases caused by clostridium difficile
CN105849086B (zh) 2012-11-24 2018-07-31 杭州多禧生物科技有限公司 亲水性链接体及其在药物分子和细胞结合分子共轭反应上的应用
EP2958905B1 (en) 2013-02-22 2017-03-29 Amgen Inc. Carbohydrate phosphonate derivatives as modulators of glycosylation
EP3331893B1 (en) 2015-08-05 2019-05-22 Enterome Mannose derivatives useful for treating pathologies associated with adherent e. coli

Also Published As

Publication number Publication date
WO2020104697A1 (en) 2020-05-28
AU2019383549A1 (en) 2021-06-10
JP2022516837A (ja) 2022-03-03
JP7296459B2 (ja) 2023-06-22
BR112021008279A2 (pt) 2021-08-03
KR20210094573A (ko) 2021-07-29
US20230045939A1 (en) 2023-02-16
CA3120451A1 (en) 2020-05-28
EP3883944A1 (en) 2021-09-29
EA202191393A1 (ru) 2021-10-12
CN113166186A (zh) 2021-07-23

Similar Documents

Publication Publication Date Title
NZ734892A (en) Amatoxin-antibody conjugates
NZ754051A (en) Novel antibodies and uses thereof
WO2020056198A3 (en) Substituted benzazepine compounds, conjugates, and uses thereof
CL2018000108A1 (es) Moléculas de anticuerpo que se unen a cd22
AR124676A2 (es) Formulación farmacéutica que comprende una droga biofarmacéutica
BR112018068278A2 (pt) derivado de 3-desóxi e suas composições farmacêuticas
EP3835322A3 (en) Anti-b7-h3 antibodies and antibody drug conjugates
WO2018226622A8 (en) Compounds for treating huntington's disease
BR112017002080A2 (pt) ?anticorpo monoclonal ou fragmento de ligação, molécula de ácido nucleico isolada, vetor, célula hospedeira, métodos para preparar o anticorpo monoclonal ou fragmento de ligação, in vivo ou in vitro e para prevenção e/ou tratamento e/ou terapia adjuvante e/ou diagnóstico de um tumor, conjugado, kit, uso de um anticorpo monoclonal ou fragmento de ligação, e, composição farmacêutica?
MX2019004779A (es) Composicion farmaceutica para tratamiento y/o prevencion de cancer.
CL2018000107A1 (es) Moléculas de anticuerpo que se unen a cd79
MX350200B (es) Anticuerpos humanos y conjugados de anticuerpo-farmaco contra cd74.
GEP20146181B (en) Anti cxcr4 antibodies for treatment of hiv
BRPI1014544B8 (pt) anticorpo anti-il-17f monoclonal totalmente humano isolado e composição farmacêutica compreendendo o mesmo
BR112018075651A2 (pt) anticorpos anti-cd98 e conjugados anticorpo fármaco
SG178886A1 (en) Humanized anti-cdcp1 antibodies
EA201992570A1 (ru) Составы на основе человеческих антител к rankl, а также способы их применения
PH12014502352A1 (en) Aqueous pharmaceutical composition containing a biologic therapeutic agent and guanidine or a guanidine derivative and an injection including the composition
BR112018010394A2 (pt) anticorpo, conjugado anticorpo-fármaco, composição farmacêutica, e, combinação do anticorpo.
BR112015032200A2 (pt) conjugado anticorpo-droga com estabilidade melhorada, método de preparação, composição farmacêutica e uso do mesmo
WO2016198170A8 (en) Vaccines against streptococcus pneumoniae serotype 5
EA201300132A1 (ru) Фармацевтическая композиция и методы лечения и профилактики заболеваний, вызванных вич или ассоциированных с вич
MX2021011995A (es) Composicion farmaceutica acuosa de anticuerpo anti-il17a y su uso.
PH12018501205A1 (en) Synthetic vaccines against streptococcus pneumoniae serotype 2
MX2016000099A (es) Vacunas sinteticas contra streptococcus pneumoniae tipo 1.